Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
-
Ann. Allergy Asthma Immunol. · Feb 2001
Randomized Controlled Trial Clinical TrialA comprehensive inner-city asthma program reduces hospital and emergency room utilization.
To evaluate the efficacy of a comprehensive asthma program on emergency department (ED) visits and hospital admission rates in an inner-city pediatric population. ⋯ A comprehensive asthma care program is efficacious in reducing hospital utilization.
-
Ann. Allergy Asthma Immunol. · May 2000
Randomized Controlled Trial Multicenter Study Clinical TrialFexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria.
Fexofenadine is a nonsedating antihistamine approved for treatment of seasonal allergic rhinitis. ⋯ Fexofenadine HCl significantly reduced pruritus severity, number of wheals, and interference with sleep and normal daily activities in patients with chronic urticaria compared with placebo. Twice-daily doses of 60 mg or greater were most effective.
-
Ann. Allergy Asthma Immunol. · Jun 1999
Randomized Controlled Trial Clinical TrialRisk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders.
Previous studies show skin reactions after exposure to acetaminophen and/or nimesulide to occur in about 10% of patients with a history of urticaria induced by aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs). This fact is surprising since cross-reactivity among different NSAIDs should not occur among subjects without a history of chronic urticaria. ⋯ In at least 20% of patients with a history of urticaria/angioedema or anaphylaxis induced by aspirin or other NSAIDs, but without a history of chronic urticaria, cross-reactivity with other NSAIDs occurs. Atopy as well as a history of aspirin-induced anapylactoid reactions seem to represent relevant risk factors for intolerance to alternative NSAIDs. In view of these findings, aspirin-intolerant patients with such clinical features should be submitted to peroral tolerance tests with at least two alternative substances in order to avoid potentially severe reactions.
-
Ann. Allergy Asthma Immunol. · Mar 1999
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialInhaled salmeterol and fluticasone: a study comparing monotherapy and combination therapy in asthma.
The current stepwise approach to pharmacotherapy in the treatment of asthma includes the initiation of an inhaled corticosteroid with the addition of a long-acting inhaled bronchodilator if low dose inhaled corticosteroid fails to control asthma symptoms. ⋯ Initiation of maintenance therapy with salmeterol and fluticasone propionate in patients with asthma treated with short-acting beta2-agonists alone provides greater improvements in pulmonary function and symptom control than initiation of maintenance therapy with fluticasone propionate alone.
-
Ann. Allergy Asthma Immunol. · Mar 1999
Randomized Controlled Trial Clinical TrialDiskus and diskhaler: efficacy and safety of fluticasone propionate via two dry powder inhalers in subjects with mild-to-moderate persistent asthma.
Fluticasone propionate is a topically active glucocorticoid with potent antiinflammatory activity in the treatment of asthma. ⋯ Fluticasone propionate powder, administered via the Diskus or Diskhaler inhalation devices, was well tolerated and effective in the treatment of mild-to-moderate persistent asthma.